Cellectar to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
July 08, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., July 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
Cellectar Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of Directors
June 24, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., June 24, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs...
Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2021 09:00 ET
|
Cellectar Biosciences
Mean treatment free remission 1.1 years and remains ongoing Progression free survival for MYD88 wild type and high-risk patients 18 months and ongoing FLORHAM PARK, N.J., June 04, 2021 (GLOBE...
Cellectar Announces Poster Presentation of CLR 131 Data in Waldenstrom’s Macroglobulinemia at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
May 20, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...
Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021
May 14, 2021 09:00 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...
Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update
May 10, 2021 08:30 ET
|
Cellectar Biosciences
Initiated pivotal study of CLR 131 in Waldenstrom’s macroglobulinemia (WM)Received European Orphan Drug Designation for CLR 131 in WM Strong cash position of approximately $54 million providing cash...
Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico
April 27, 2021 08:39 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar to Participate at Upcoming Institutional Investor Conferences
March 11, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Granted Japanese Composition of Matter Patent for its Phospholipid-Ether Drug Conjugates
March 09, 2021 09:00 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., March 09, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar to Participate at Upcoming Institutional Investor Conferences
March 05, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...